Market cap
$12 Mln
Revenue (TTM)
$37 Mln
P/E Ratio
--
P/B Ratio
0.2
Div. Yield
0 %
| Bon Natural Life (BON) | Theravance Biopharma (TBPH) | Aptorum Group Limited Class A - ADR | Universe Pharmaceuticals Inc (UPC) | |
|---|---|---|---|---|
Market cap ($ Mln) |
12 | 885 | 1 | 3 |
Revenue ($ Mln) |
19 | 104 | 1 | 18 |
Net Profit ($ Mln) |
-1.99 | 53.81 | -5.68 | -3.67 |
Net Margin (%) |
15.45 | 51.58 | -591.67 | -- |
RoE (%) |
-3.93 | 18.35 | -49.04 | -7.23 |
Price to Earnings |
-- | 16.39 | -- | -- |
Price-To-Book |
0.16 | 3.05 | 0.28 | 0.06 |
Cashflow ($ Mln)
| Bon Natural Life (BON) | Theravance Biopharma (TBPH) | Aptorum Group Limited Class A - ADR | Universe Pharmaceuticals Inc (UPC) | |
|---|---|---|---|---|
|
Cash From Operating Activities
|
0.14 | 238.54 | -1.84 | -5.05 |
|
Cash Flow from Investing Activities
|
-10.00 | -105.28 | -- | -0.34 |
|
Cash from Financing Activities
|
15.45 | -3.25 | 4.41 | 9.73 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- |
Ratios
Profitability Ratios
| Bon Natural Life (BON) | Theravance Biopharma (TBPH) | Aptorum Group Limited Class A - ADR | Universe Pharmaceuticals Inc (UPC) | |
|---|---|---|---|---|
|
ROCE (%)
|
-3.29 | 35.44 | -5.34 | -6.62 |
|
ROE (%)
|
-3.93 | 44.85 | -6.16 | -7.23 |
|
ROA (%)
|
-2.71 | 25.22 | -7.83 | -5.35 |
|
EBIT Margin (%)
|
-- | -- | -- | -- |
|
Net Margin (%)
|
-10.68 | 98.54 | -- | -20.56 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- |
Growth Ratios
| Bon Natural Life (BON) | Theravance Biopharma (TBPH) | Aptorum Group Limited Class A - ADR | Universe Pharmaceuticals Inc (UPC) | |
|---|---|---|---|---|
|
Revenue Growth (%)
|
-0.22 | 0.67 | -- | -0.22 |
|
EBIT Growth (%)
|
-- | -- | -- | -- |
|
Net Profit Growth (%)
|
-600.98 | 287.70 | 68.06 | 57.92 |
|
EPS Growth (%)
|
-20.16 | 2.74 | 0.98 | 0.27 |
|
Book Value Growth (%)
|
-- | -- | -- | -- |
Valuation Ratios
| Bon Natural Life (BON) | Theravance Biopharma (TBPH) | Aptorum Group Limited Class A - ADR | Universe Pharmaceuticals Inc (UPC) | |
|---|---|---|---|---|
|
Price / Earnings
|
-0.33 | 9.37 | -5.72 | 0.00 |
|
Price / Book Value
|
0.01 | 3.35 | 0.34 | 0.00 |
|
Dividend Yield (%)
|
-- | -- | -- | -- |
|
EV/EBITDA
|
-116.08 | 5.49 | -4.28 | 8.32 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- |
Solvency Ratios
| Bon Natural Life (BON) | Theravance Biopharma (TBPH) | Aptorum Group Limited Class A - ADR | Universe Pharmaceuticals Inc (UPC) | |
|---|---|---|---|---|
|
Debt to Equity
|
0.21 | 0.25 | 0.15 | 0.16 |
|
Short term debt to equity ratio
|
0.20 | 0.04 | 0.15 | 0.16 |
|
Current Ratio
|
1.74 | 10.93 | 0.78 | 4.07 |
|
Quick Ratio
|
1.01 | -- | -- | 3.90 |
|
Interest Coverage
|
-3.67 | 53.52 | -- | -14.83 |
Operating Efficiency Ratios
| Bon Natural Life (BON) | Theravance Biopharma (TBPH) | Aptorum Group Limited Class A - ADR | Universe Pharmaceuticals Inc (UPC) | |
|---|---|---|---|---|
|
Debtors to sales (%)
|
61.81 | 88.90 | -- | 73.84 |
|
Asset Turnover
|
0.25 | 0.26 | 0.00 | 0.26 |
|
Receivable days
|
228.44 | 278.67 | -- | 266.82 |
|
Inventory Days
|
257.00 | -4,537.51 | -- | 62.10 |
|
Payable days
|
136.67 | 159.28 | -- | 104.04 |
|
Cash Conversion Cycle
|
348.77 | -4,418.12 | -- | 224.88 |